Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers

Trial Profile

Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Metformin (Primary) ; Sapanisertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 1 Sep 2021 to 1 Mar 2023.
    • 04 Oct 2017 Planned primary completion date changed from 1 Sep 2021 to 1 Mar 2022.
    • 04 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top